Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Liye Chen has been awarded a Versus Arthritis five-year career development fellowship to identify and validate new T cell therapeutic targets in ankylosing spondylitis (AS).

AS is a painful and progressive form of inflammatory arthritis, affecting around 200,000 people in the UK. The disease causes inflammation in the spine and other joints, leading to pain, stiffness, and fatigue.

Although treatment for AS has greatly improved in the past decade, a definitive cure has not yet been found and many patients suffer persistent symptoms or unacceptable side effects from current therapies.

AS has a strong genetic basis, with over 100 genetic variations linked to the condition. Through bioinformatics integration of genetic data and gene expression profiles of T cells from blood and joint fluid from patients with AS, the innovative programme of research will allow Dr Chen to identify novel T cell regulators in AS which are potential therapeutic targets.

Dr Chen says: “It’s very exciting to be able to look at AS through different lenses and bring such cutting-edge technologies to the table. The integration of multiple datasets (GWAS, eQTL and RNA sequencing of patient-derived T cells) and functional screen of identified genes using disease relevant cellular assays will allow us to identify genes that contribute to AS pathogenesis much faster than currently possible.”

Once the novel AS T cell regulators have been identified and validated in cellular assays, Dr Chen will focus on the most promising and novel regulators for their functional mechanisms and therapeutic potentials.

“I’m very grateful to Versus Arthritis for granting me the opportunity to contribute to such an important field or research, aiding their aims of finding a cure for major forms of arthritis and helping thousands of patients worldwide.” concludes Dr Chen.

Funded by

Versus Arthritis logo

Similar stories

Fiona Powrie honoured by British Society for Immunology

Fiona Powrie was one of four researchers from the University of Oxford recognised for their outstanding contributions to immunology with Honorary Lifetime Membership of the British Society for Immunology.

The Kennedy Institute scoops sustainability award

A new roof extension was awarded the 2021 Green Award for Sustainability by the Oxford Preservation Trust alongside a Certificate in the New Building category.

Vaccination safety: generating accurate evidence is the clearest path to creating public trust

A new study shows that a vaccine surveillance method in observational data may generate high number of false positives

Fiona Powrie appointed new Deputy Chair of Wellcome’s Board of Governors

Fiona Powrie, Director of the Kennedy Institute of Rheumatology at the University of Oxford has been selected as the next Deputy Chair of Wellcome’s Board of Governors.

A drug being trialled to treat cancer, could be the key to reducing gut inflammation

Published in Nature Communications, a new study reveals a new signalling pathway behind macrophage inflammatory activity

Single-cell ancestry vaccine research funded by the Chan Zuckerberg Initiative

The Chan Zuckerberg Initiative (CZI) has provided $2 million in funding to investigate how our ancestry and diversity influence the way that vaccines work in our cells.